Revolution Medicines, Inc. (RVMD)
收市後：
| 前收市價 | 30.48 |
| 開市 | 30.47 |
| 買盤 | 29.90 x 900 |
| 賣出價 | 31.93 x 1100 |
| 今日波幅 | 29.60 - 30.48 |
| 52 週波幅 | 17.47 - 35.50 |
| 成交量 | |
| 平均成交量 | 1,029,254 |
| 市值 | 3.276B |
| Beta 值 (5 年，每月) | 1.36 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.08 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 36.00 |
Insider MonkeyRevolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised […]
Insider MonkeyRevolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript November 7, 2022 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.87 EPS, expectations were $-0.84. Operator: Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast. I would now like to hand the conference over […]
BenzingaRevolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Revolution Medicines Inc (NASDAQ: RVMD) announced that Sanofi SA (NASDAQ: SNY) has terminated global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding R&D and rights to all commercial proceeds from RMC-4630, an SHP2 inhibitor drug candidate in development for certain RAS-addicted cancers. The companies plan to collaborate to transition Sanofi's
